1
|
Niot C, Cuvelier E, Leroy A, Vaiva G, Maron M, Cottencin O, Odou P, Amad A, Décaudin B. Clinical pharmacy activities specific to patients treated with lithium. L'ENCEPHALE 2025:S0013-7006(25)00012-0. [PMID: 40089436 DOI: 10.1016/j.encep.2024.11.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 11/08/2024] [Accepted: 11/21/2024] [Indexed: 03/17/2025]
Abstract
OBJECTIVES Medication compliance in lithium-treated patients is poor (43-46%) and may be responsible for relapse or toxicity. Improving understanding of treatment principles leads to increased medication adherence. To do this, targeted and personalised pharmaceutical interviews on lithium were developed and implemented by a clinical pharmacy team in adult psychiatric departments of the Lille university hospital center. The primary aim of this work was to assess medication adherence with lithium, patients' understanding of the drug and of potential adverse effects. A secondary objective was to evaluate the feasibility of these pharmaceutical interviews in practice. METHODS Implementation of self-assessment questionnaires measuring medication adherence (Medication Adherence Rating Scale) as well as knowledge of lithium and risk of exposure to toxic effects (Lithium Knowledge Test) of patients. Conducting targeted pharmaceutical interviews about lithium, and recording of time spent, satisfaction of medical teams and difficulties encountered. RESULTS Twenty patients were included in the 6-month study. Every patient benefited from a personalized pharmaceutical interview by a pharmacy intern focused on lithium during his hospitalization. Lithium adherence, patient knowledge and risk exposure to lithium toxicity was 5.5±0.9 (target ≥8), 8.9±0.9 (target >6) and 4.0±0.5 (target <4). The median time required for these new activities was 95minutes per patient. Medical satisfaction was observed in 70% to 100% of cases depending on the criterion assessed. The lack of pharmaceutical time and communication difficulties were the main obstacles encountered. CONCLUSION Medication compliance in patients treated with lithium is poor as described in the literature. To improve this and to optimise drug management, patients have benefited from targeted and personalised pharmaceutical interviews. The satisfaction of patients and the medical team made it possible to sustain these new pharmaceutical activities.
Collapse
Affiliation(s)
- Candice Niot
- Service pharmacie, CHU de Nice, 06001 Nice, France.
| | - Elodie Cuvelier
- ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, University Lille, CHU Lille, 59000 Lille, France
| | - Arnaud Leroy
- Service de psychiatrie, University Lille, CHU Lille, 59000 Lille, France
| | - Guillaume Vaiva
- Service de psychiatrie, University Lille, CHU Lille, 59000 Lille, France
| | - Michel Maron
- Service de psychiatrie, University Lille, CHU Lille, 59000 Lille, France
| | - Oliver Cottencin
- Service addictologie, University Lille, CHU Lille, 59000 Lille, France
| | - Pascal Odou
- ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, University Lille, CHU Lille, 59000 Lille, France
| | - Ali Amad
- Service de psychiatrie, University Lille, CHU Lille, 59000 Lille, France
| | - Bertrand Décaudin
- ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, University Lille, CHU Lille, 59000 Lille, France
| |
Collapse
|
2
|
Zolezzi M, Eltorki YH, Almaamoon M, Fathy M, Omar NE. Outcomes of patient education practices to optimize the safe use of lithium: A literature review. Ment Health Clin 2018; 8:41-48. [PMID: 29955544 PMCID: PMC6007520 DOI: 10.9740/mhc.2018.01.041] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
INTRODUCTION Lithium is commonly used to treat various psychiatric disorders and is particularly effective in the maintenance phase of bipolar disorder. Unfortunately, this drug has a narrow therapeutic index and, if not monitored regularly, can result in toxicity. Therefore, for lithium to be prescribed safely, clinicians must ensure that patients are well educated on lithium toxicity, its prevention, and symptom recognition. This article summarizes studies that investigated lithium education strategies to help promote the safe use of lithium. METHODS Four electronic databases were searched using key terms and subject headings. Reference lists of relevant papers were also reviewed. The search was limited to literature published in English, without year limits. Eligible studies examined lithium patient education and the impact on patients' knowledge of safe lithium use. RESULTS Of a total of 517 citations that were retrieved from the electronic database search, 12 were selected for inclusion in this review. Most of the studies included assessed the effect of lithium education on various aspects of patients' knowledge, including but not limited to, lithium toxicity. Of the studies assessing the correlation between lithium knowledge and lithium levels, most demonstrated a positive correlation between lithium knowledge and lithium levels that were more stable and within the higher end of the recommended therapeutic range. CONCLUSIONS Studies evaluating lithium patient education and its effect on improving the safe use of lithium are limited. Nevertheless, this literature review highlights that lithium patient education is critical to promote its safe use.
Collapse
Affiliation(s)
- Monica Zolezzi
- Assistant Professor, College of Pharmacy, Qatar University, Doha, Qatar; Clinical Pharmacist, Hamad Medical Corporation Mental Health Hospital, Doha, Qatar,
| | | | | | - Mahmoud Fathy
- Pharmacist HMC, Pharmacy, Al Wakra Hospital, Doha, Qatar
| | - Nabil E Omar
- Clinical Pharmacist, Hamad Medical Corporation-National Center for Cancer Care and Research Hospital, Doha, Qatar
| |
Collapse
|
3
|
Chakrabarti S. Treatment-adherence in bipolar disorder: A patient-centred approach. World J Psychiatry 2016; 6:399-409. [PMID: 28078204 PMCID: PMC5183992 DOI: 10.5498/wjp.v6.i4.399] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Revised: 10/31/2016] [Accepted: 11/22/2016] [Indexed: 02/05/2023] Open
Abstract
About half of the patients diagnosed with bipolar disorder (BD) become non-adherent during long-term treatment, a rate largely similar to other chronic illnesses and one that has remained unchanged over the years. Non-adherence in BD is a complex phenomenon determined by a multitude of influences. However, there is considerable uncertainty about the key determinants of non-adherence in BD. Initial research on non-adherence in BD mostly limited itself to examining demographic, clinical and medication-related factors impacting adherence. However, because of inconsistent results and failure of these studies to address the complexities of adherence behaviour, demographic and illness-related factors were alone unable to explain or predict non-adherence in BD. This prompted a shift to a more patient-centred approach of viewing non-adherence. The central element of this approach includes an emphasis on patients’ decisions regarding their own treatment based on their personal beliefs, life circumstances and their perceptions of benefits and disadvantages of treatment. Patients’ decision-making processes are influenced by the nature of their relationship with clinicians and the health-care system and by people in their immediate environment. The primacy of the patient’s perspective on non-adherence is in keeping with the current theoretical models and concordance-based approaches to adherence behaviour in BD. Research over the past two decades has further endorsed the critical role of patients’ attitudes and beliefs regarding medications, the importance of a collaborative treatment-alliance, the influence of the family, and the significance of other patient-related factors such as knowledge, stigma, patient satisfaction and access to treatment in determining non-adherence in BD. Though simply moving from an illness-centred to a patient-centred approach is unlikely to solve the problem of non-adherence in BD, such an approach is more likely to lead to a better understanding of non-adherence and more likely to yield effective solutions to tackle this common and distressing problem afflicting patients with BD.
Collapse
|
4
|
Rosa AR, Sánchez-Moreno J, Martínez-Aran A, Salamero M, Torrent C, Reinares M, Comes M, Colom F, Van Riel W, Ayuso-Mateos JL, Kapczinski F, Vieta E. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health 2007; 3:5. [PMID: 17555558 PMCID: PMC1904447 DOI: 10.1186/1745-0179-3-5] [Citation(s) in RCA: 587] [Impact Index Per Article: 32.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2007] [Accepted: 06/07/2007] [Indexed: 11/18/2022]
Abstract
Background Numerous studies have documented high rates of functional impairment among bipolar disorder (BD) patients, even during phases of remission. However, the majority of the available instruments used to assess functioning have focused on global measures of functional recovery rather than specific domains of psychosocial functioning. In this context, the Functioning Assessment Short Test (FAST) is a brief instrument designed to assess the main functioning problems experienced by psychiatric patients, particularly bipolar patients. It comprises 24 items that assess impairment or disability in six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time. Methods 101 patients with DSM-IV TR bipolar disorder and 61 healthy controls were assessed in the Bipolar Disorder Program, Hospital Clinic of Barcelona. The psychometric properties of FAST (feasibility, internal consistency, concurrent validity, discriminant validity (euthymic vs acute patients), factorial analyses, and test-retest reliability) were analysed. Results The internal consistency obtained was very high with a Cronbach's alpha of 0.909. A highly significant negative correlation with GAF was obtained (r = -0.903; p < 0.001) pointing to a reasonable degree of concurrent validity. Test-retest reliability analysis showed a strong correlation between the two measures carried out one week apart (ICC = 0.98; p < 0.001). The total FAST scores were lower in euthymic (18.55 ± 13.19; F = 35.43; p < 0.001) patients, as compared with manic (40.44 ± 9.15) and depressive patients (43.21 ± 13.34). Conclusion The FAST showed strong psychometrics properties and was able to detect differences between euthymic and acute BD patients. In addition, it is a short (6 minutes) simple interview-administered instrument, which is easy to apply and requires only a short period of time for its application.
Collapse
Affiliation(s)
- Adriane R Rosa
- Bipolar Disorders Program & Molecular Psychiatry Laboratory, Hospital Clinic of Porto Alegre, Ramiro Barcelos, 2350, 90035-003, Porto Alegre, RS, Brazil
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
| | - Jose Sánchez-Moreno
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
- Department of Psychiatry. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa, Madrid, Spain
| | - Anabel Martínez-Aran
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
| | - Manel Salamero
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
| | - Carla Torrent
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
| | - Maria Reinares
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
| | - Mercè Comes
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
| | - Francesc Colom
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
| | - Willemijn Van Riel
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
| | - Jose Luis Ayuso-Mateos
- Department of Psychiatry. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa, Madrid, Spain
| | - Flávio Kapczinski
- Bipolar Disorders Program & Molecular Psychiatry Laboratory, Hospital Clinic of Porto Alegre, Ramiro Barcelos, 2350, 90035-003, Porto Alegre, RS, Brazil
| | - Eduard Vieta
- Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain
| |
Collapse
|